Translated title of the contribution: Antiepileptic efficacy and side effects of barbexaclone: Preliminary report

G. Avanzini, G. Battaglia, S. Franceschetti

Research output: Contribution to journalArticlepeer-review


40 subjects (26 M, 16 F) aged between 12 and 60 have been treated with Maliasin R (barbiturate salt of propylhexedrine at ratio 3:2). 15 patients showed generalized seizures (primary generalized in 9 cases), 25 showed partial seizures with elementary or complex symptomatology. All the cases but two were chronically treated with AED. Maliasin R was substituted to PB in 32 cases, and added to the previous therapy in 6 cases. In 16 cases it has been administered in monotherapy; the mean duration of the treatment with Maliasin R was 22.9±18.6 months. No patients worsened, 18 had at least a 50% reduction of the seizure frequency. In two subjects, free of seizures during previous PB treatment, the switch to Maliasin R maintained the control eliminating the side effects (serious drowsiness). During Maliasin R treatment no patient accused drowsiness or sedation, though in 14 out of the 40 cases the relative daily dose of PB was increased in 1:1.2 - 1:2 ratio. Side effects recorded during Maliasin R treatment were usually mild. Only in two patients the treatment to be discontinued owing to the side effects. The plasma levels of PB found during Maliasin R treatment showed a dose/level ratio comparable with the one expected for the administration of simple PB.

Translated title of the contributionAntiepileptic efficacy and side effects of barbexaclone: Preliminary report
Original languageItalian
Pages (from-to)341-343
Number of pages3
JournalBollettino - Lega Italiana contro l'Epilessia
VolumeNO. 45-46
Publication statusPublished - 1984

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'Antiepileptic efficacy and side effects of barbexaclone: Preliminary report'. Together they form a unique fingerprint.

Cite this